A Phase II/III Adaptive Seamless Design, Randomized, Controlled Trial To Evaluate Safety and Immunogenicity of 2 Dose-Regimen of BBV87 Chikungunya vaccine in healthy subjects aged 12 to 65 years in Panama, Colombia, and Thailand

Part C